Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 12/20 | 0.57 |
| ▸ | HTR1D | P28221 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | BDKRB1 | P46663 | 3/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2238032 | 0.88 | NISCH (0.56) | NISCHHTR1DADRA1ABDKRB1PPARG | |
| SCHEMBL3260321 | 0.83 | NISCH (0.61) | NISCHHTR1DADRA1ABDKRB1PPARG | |
| SCHEMBL1936403 | 0.83 | NISCH (0.55) | NISCHHTR1DADRA1ABDKRB1PPARG | |
| SCHEMBL2237206 | 0.81 | NISCH (0.35) | NISCHBDKRB1 | |
| SCHEMBL2237521 | 0.79 | AOC3 (0.40) | NISCH | |
| SCHEMBL1936400 | 0.77 | NISCH (0.53) | NISCHHTR1DADRA1ABDKRB1 | |
| SCHEMBL1936162 | 0.76 | NISCH (0.60) | NISCHHTR1DADRA1ABDKRB1 | |
| SCHEMBL19921435 | 0.75 | CYP2C9 (0.49) | — | |
| SCHEMBL1936399 | 0.75 | NISCH (0.53) | NISCHHTR1DADRA1APPARG | |
| SCHEMBL11557262 | 0.74 | NISCH (0.55) | NISCHHTR1DADRA1APPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8623859-B2 | Bradykinin B1 antagonists | EVOTEC AG (DE) | 2014-01-07 | — | — | US | disclosed |
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | BDKRB1, BDKRB2, BRS3 | NISCH 317/4885HTR1D 242/4885ADRA1A 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.